Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 6/20 | 0.64 |
| ▸ | REN | P00797 | 4/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.64 |
| ▸ | F2 | P00734 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | LTA4H | P09960 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | PEPD | P12955 | 1/20 | 0.64 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.64 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.64 |
| ▸ | HTR2A | P28223 | 1/20 | 0.64 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.64 |
| ▸ | HRH1 | P35367 | 1/20 | 0.64 |
| ▸ | THPO | P40225 | 1/20 | 0.64 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.64 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.64 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17037465 | 1.00 | ACE (0.64) | ACERENKDM4EF2LMNA | |
| SCHEMBL17037464 | 1.00 | ACE (0.64) | ACERENKDM4EF2LMNA | |
| SCHEMBL6782714 | 0.93 | ACE (0.68) | ACERENKDM4EF2LMNA | |
| SCHEMBL6782708 | 0.93 | ACE (0.68) | ACERENKDM4EF2LMNA | |
| SCHEMBL11301920 | 0.86 | ACE (0.65) | ACERENKDM4EF2LMNA | |
| SCHEMBL11379775 | 0.86 | ACE (0.65) | ACERENKDM4EF2LMNA | |
| SCHEMBL11379763 | 0.86 | ACE (0.65) | ACERENKDM4EF2LMNA | |
| SCHEMBL17015162 | 0.86 | ACE (0.47) | ACERENKDM4EF2LMNA | |
| SCHEMBL967588 | 0.85 | ACE (0.68) | ACERENKDM4EF2LMNA | |
| SCHEMBL17323620 | 0.85 | ACE (0.68) | ACERENKDM4EF2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240016942-A1 | STAT DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240016942-A1 | STAT DEGRADERS AND USES THEREOF | STAT4, STAT1, STAT3 | ACE 206/4885REN 2661/4885KDM4E 414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.